| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.41B | 5.44B | 5.38B | 3.71B | 2.95B | 2.79B |
| Gross Profit | 535.50M | 4.56B | 1.50B | 977.00M | 714.80M | 653.00M |
| EBITDA | 698.00M | 1.10B | 1.16B | 747.00M | 676.80M | 586.50M |
| Net Income | 205.00M | 307.00M | 381.00M | 232.00M | 263.00M | 186.00M |
Balance Sheet | ||||||
| Total Assets | 14.23B | 10.55B | 11.13B | 11.92B | 4.32B | 5.84B |
| Cash, Cash Equivalents and Short-Term Investments | 1.69B | 911.00M | 1.56B | 2.09B | 597.90M | 2.34B |
| Total Debt | 6.08B | 4.11B | 4.73B | 5.40B | 1.93B | 3.40B |
| Total Liabilities | 8.97B | 6.33B | 7.04B | 7.82B | 3.06B | 4.71B |
| Stockholders Equity | 5.27B | 4.23B | 4.09B | 4.10B | 1.26B | 1.13B |
Cash Flow | ||||||
| Free Cash Flow | 475.50M | 463.00M | 526.00M | 410.00M | 403.30M | 391.70M |
| Operating Cash Flow | 616.50M | 678.00M | 737.00M | 600.00M | 563.20M | 544.20M |
| Investing Cash Flow | -362.09M | -373.00M | -416.00M | -1.20B | -441.10M | -327.00M |
| Financing Cash Flow | -312.78M | -752.00M | -361.00M | 1.32B | -417.10M | 62.20M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | £521.59M | 15.59 | 12.46% | 3.11% | 6.55% | 18.44% | |
76 Outperform | £2.11B | 21.25 | 20.62% | 2.59% | 11.42% | -17.18% | |
74 Outperform | £10.75B | 42.06 | 5.93% | 1.73% | -1.58% | -34.64% | |
74 Outperform | £6.95B | 20.07 | 29.71% | 3.56% | 1.14% | 17.74% | |
73 Outperform | £2.50B | 52.87 | 5.21% | 1.38% | 0.84% | -62.73% | |
66 Neutral | £380.65M | 40.52 | 4.01% | 2.12% | 6.90% | 145.00% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% |
Rentokil Initial reported a 4.6% increase in Group Revenues for the third quarter of 2025, driven by organic growth and strategic initiatives in North America and international markets. The company maintained strong performance in pest control and hygiene services, with a focus on improving sales execution, digital marketing, and cost efficiency. The sale of its France Workwear business was completed, contributing to a reduction in net debt, while the company continues to expect financial results in line with market expectations for the year.
Rentokil Initial has completed the sale of its France Workwear business to H.I.G. Capital for an enterprise value of €410 million. This strategic move allows Rentokil Initial to focus on its core pest control and hygiene & wellbeing services, enhancing cash generation and capital efficiency while reducing annual capital expenditure.
Rentokil Initial plc announced that its Chief Executive, Andy Ransom, acquired 8,997 ordinary shares through the Company’s Dividend Reinvestment Plan (DRIP) at a price of £3.616967 per share. This transaction, conducted on the London Stock Exchange, reflects a reinforcement of confidence in the company’s financial strategies and market position, potentially impacting stakeholder perceptions positively.
John Pettigrew, the Senior Independent Director at Rentokil Initial, has been appointed as a non-executive director on the board of BAE Systems plc, effective from February 23, 2026. This appointment may enhance Rentokil Initial’s strategic connections and influence within the industry, potentially impacting its market positioning and stakeholder relations.